Porcine neural cell product-PD

Drug Profile

Porcine neural cell product-PD

Alternative Names: NeuroCell-PD

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Diacrin; Genzyme Corporation
  • Developer Diacrin
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Parkinson's disease

Most Recent Events

  • 06 Aug 2002 Suspended - Phase-II for Parkinson's disease in USA (Intracerebal)
  • 27 Mar 2001 Data have been added to the therapeutic trials and adverse events sections
  • 06 Dec 1999 NeuroCellTM-PD has been assigned Fast-Track designation by the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top